LISTED medical dermatology company Botanix Pharmaceuticals has announced the receipt of a Research and Development Tax Incentive cash refund of $4.6m for the financial year 2017/2018.
The money will be channelled back into the research program with strong initial recruitment progress made in the firm's BTX 1503 acne Phase II clinical study and the BTX 1308 psoriasis study.
The above article was sent to subscribers in Pharmacy Daily's issue from 26 Nov 18
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 26 Nov 18
